Moderna Inc. ($MRNA) Stock Forecast: Up 10.8% Today

What is Moderna Inc.?

Moderna, Inc. is a leading biotechnology company known for its innovative mRNA platform, which has gained significant attention for its role in developing vaccines and therapeutics.

Why is Moderna Inc. going up?

MRNA stock is up 10.8% on Jun 17, 2026 19:46

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Concentra Group Holdings Parent Inc stock hits all-time high at 28.62 USD

Concentra Group Holdings Parent Inc.'s stock has reached an all-time high of $28.64, driven by a 37% 1-year change and a 45% year-to-date return. The company, which boasts a "GREAT" financial health rating and a perfect Piotroski Score of 9, recently reported strong Q1 2026 earnings, exceeding expectations with $0.40 EPS and $569.6 million in revenue. Analysts from Mizuho, Truist Securities, and Goldman Sachs have responded by raising price targets and initiating buy ratings, underscoring positive operational performance and future prospects.

https://www.investing.com/news/company-news/concentra-group-holdings-parent-inc-stock-hits-alltime-high-at-2862-usd-93CH-4747630

ICCM Stock Explodes As New Cancer Data Fuels Trading Frenzy

IceCure Medical Ltd. (ICCM) stock surged by 235.21% due to positive clinical data for its ProSense cryoablation system, including nearly 90% recurrence-free outcomes in small kidney tumors and promising results in breast cancer and fibroadenomas. This data, coupled with recent FDA clearance for ProSense in early-stage breast cancer, has fueled significant trading momentum. While the company is still early-stage financially, the clinical validation has led to aggressive buying and high volatility among traders.

https://stockstotrade.com/news/icecure-medical-ltd-iccm-news-2026_06_17/

Moderna to Host Investor Event - Science Day

Moderna, Inc. announced it will host an Investor Event - Science Day on Thursday, June 25, 2026, at 9:00 AM ET. The event will showcase the company's research and early development programs, highlighting how its mRNA platform, combined with AI and robotics, is driving innovation and expanding into new therapeutic areas. A live webcast will be available on Moderna's investor relations website, with a replay archived for at least 30 days.

https://investingnews.com/moderna-to-host-investor-event-science-day/

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

This article covers several key developments in the biopharma industry, including Moderna's alignment with the FDA for its mRNA flu vaccine ahead of an advisory committee meeting. It also highlights a surge in biotech IPOs, with Kailera Therapeutics and Parabilis Medicines setting new records, alongside ongoing biopharma layoffs primarily from Takeda and BioNTech. Additionally, the piece touches on Eli Lilly's dealmaking and positive clinical results, and concerns surrounding the FDA’s National Priority Voucher program.

https://www.biospace.com/drug-development/modernas-fda-adcomm-ipo-mania-biopharma-layoffs-more

Moderna to Host Investor Event - Science Day

Moderna, Inc. announced it will host an Investor Event - Science Day on Thursday, June 25, 2026, at 9:00 AM ET. The event will detail Moderna's research and early development programs, highlighting how its mRNA platform, augmented by AI and robotics, is driving innovation into new therapeutic areas. A live webcast and subsequent replay will be available on Moderna's investor relations website.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-to-host-investor-event-science-day-1178258

Trending Today

Adobe Inc. ($ADBE) Stock Forecast: Down 5.4% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 5.2% Today

CarMax Inc ($KMX) Stock Forecast: Down 9.9% Today

Gap Inc. ($GAP) Stock Forecast: Down 3.6% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 5.4% Today

Baxter International Inc. ($BAX) Stock Forecast: Down 5.1% Today

Franklin Resources Inc. ($BEN) Stock Forecast: Up 0.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 10.8% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 9.4% Today

Meta Platforms, Inc. ($META) Stock Forecast: Down 5.2% Today

Moderna Inc. Price History

12.05.2026 - MRNA Stock was up 5.2%

• Moderna's stock rose nearly 8%, in line with Nasdaq's recovery and positive market sentiment.
• Investor interest is high in Moderna's mRNA cancer vaccine pipeline, particularly with the approval of a new trial for mRNA-4194 in Lynch syndrome patients by UK regulators.
• Analysts are recommending a "Hold" on Moderna despite the stock's rise, with an average target price lower than the current closing value.
• The upswing in Moderna's stock may also be linked to a legal conflict with BioNTech regarding patent infringement, with Moderna asserting that its new COVID-19 vaccine does not infringe upon BioNTech's intellectual property, adding an intriguing element to the stock's movement.

16.05.2026 - MRNA Stock was up 5.7%

• Moderna's strong bullish movement today can be attributed to the strategic organizational changes announced by the company, signaling preparations for multiple product launches in 2027 and 2028.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded role of President Stephen Hoge to oversee key operations and product launches have instilled confidence in investors regarding the company's future growth prospects.
• Despite reported wider-than-expected quarterly losses and a consensus "Reduce" rating from analysts, the market seems to be focusing more on the long-term potential of Moderna's upcoming vaccine launches, leading to the positive stock movement.

17.05.2026 - MRNA Stock was up 6.1%

• This company held an Investor Event Science Day to showcase its research and development programs, particularly emphasizing innovation using mRNA technology, which likely boosted investor confidence.
• Collaboration with the FDA for an mRNA flu vaccine and positive developments in the biopharma industry, along with growing interest in biotech IPOs and ongoing industry challenges, contributed to the positive sentiment.
• Stock gains were also influenced by new product releases and advancements in the company's pipeline, strengthening its market position.
• The bullish movement observed today can be attributed to a combination of positive developments, technological advancements, and investor confidence in the biopharma industry.

16.05.2026 - MRNA Stock was up 11.4%

• Moderna's stock surge is linked to the favorable developments related to its mRNA-1010 seasonal flu vaccine. The FDA has shown support for the company's key immunogenicity data, despite some remaining uncertainties.
• Recent changes within Moderna's leadership team, such as the appointment of a new Chief Commercial Officer and expanded roles for key executives, indicate the company's strategic readiness for potential product launches. This has bolstered investor confidence in Moderna's future prospects.
• Verition Fund Management LLC has significantly increased its stake in Moderna, suggesting a growing investor interest in the company. Despite Moderna reporting a wider-than-expected quarterly loss, the positive outlook on the company's upcoming product launches appears to outweigh immediate financial concerns.

16.05.2026 - MRNA Stock was up 9.5%

• Moderna's stock saw a 9.5% surge due to favorable feedback from FDA staff regarding its flu vaccine candidate, mFlusiva, especially on its strong immune response in adults aged 65 and above. This positive development bolstered investor confidence in Moderna's vaccine projects.
• Initially met with some doubts from FDA scientists, the agreement between Moderna and the FDA on immunogenicity data pertaining to older adults before the upcoming advisory committee meeting on June 18th played a pivotal role in the stock's upward trajectory.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded responsibilities of President Stephen Hoge indicate Moderna's strategic groundwork for potential product launches, such as flu and norovirus vaccines, supporting favorable market outlook towards the company.
• The regulatory process concerning Moderna's flu vaccine, with lingering uncertainties on its long-term safety and efficacy for specific demographics, will be a crucial determinant affecting the company's stock performance in the coming period.

17.05.2026 - MRNA Stock was up 10.8%

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

17.05.2026 - MRNA Stock was up 6.3%

• Moderna's market uptick is linked to upbeat investor views following the Investor Event Science Day announcement. The event highlighted the company's research and development efforts, underscoring the potential of its mRNA platform in conjunction with AI and robotics.
• Collaboration with the FDA on its mRNA flu vaccine and the upcoming advisory committee meeting also played a role in the market's positive reaction, suggesting progress in Moderna's pipeline.
• The rise in biotech IPOs and ongoing biopharma sector developments may have contributed to the favorable climate for Moderna's stock, with investors expressing optimism about the industry's growth prospects.
• In general, Moderna's strategic actions, along with positive industry trends, likely drove today's bullish market performance.

04.05.2026 - MRNA Stock was up 9.7%

• Moderna's stock saw a 7.49% increase as investors look forward to upcoming events, such as its involvement in crucial healthcare conferences and the release of encouraging data on its melanoma treatment.
• Optimism has been reignited around Moderna's partnership with Merck for the melanoma vaccine program, showing consistent enhancements in survival rates, fueling the stock's surge.
• The President of Moderna exercising restricted stock units (RSUs), coupled with favorable updates on the company's oncology pipeline extending beyond COVID vaccines, likely bolstered bullish sentiment, propelling the stock upward today.

04.05.2026 - MRNA Stock was up 5.0%

• The positive outlook on Moderna's future, particularly in mRNA technology and vaccine advancements, likely drove the stock's bullish trajectory.
• A recent SEC filing suggesting a share sale by an individual may have been perceived as a routine financial action, minimally impacting the market movement.
• In contrast to Ultragenyx (RARE) facing stock declines post-disappointing earnings, Moderna's robust market performance signals strong investor confidence in its growth potential and continued success.
• Market optimism stemming from reports of Deutsche Bank's increased price target for Star Bulk Carriers (SBLK) and potential in tech stocks may have bolstered overall positive sentiment, positively influencing Moderna's stock.

05.05.2026 - MRNA Stock was down 5.3%

• Moderna (MRNA) stock declined amid profit-taking following recent positive data on its personalized mRNA-based cancer vaccine.
• An individual's proposed sale of 3471 shares via an SEC filing potentially influenced the stock's downward trend.
• Despite encouraging updates on its cancer vaccine and past successful trials, investor response may have been dampened by the insider selling activity.
• The combination of profit-taking, insider selling, and general market sentiment likely contributed to Moderna's bearish performance today.

09.05.2026 - MRNA Stock was down 5.0%

• The authorization granted to Moderna and the University of Oxford to initiate a Phase 1/2 study on an mRNA cancer vaccine for individuals with Lynch syndrome did not appear to have a positive impact on the stock price. This lack of significant effect might suggest that investors were anticipating more substantial news to influence the market.
• The selling of shares by Moderna's Chief Legal Officer, Shannon Thyme Klinger, could have contributed to the negative market sentiment. This insider trading activity might have been perceived as a signal of uncertainty regarding the company's future outlook.
• Despite noteworthy advancements in cancer vaccine trials and the appointment of a seasoned professional from Procter & Gamble to Eikon Therapeutics' Board of Directors, the focus on the Chief Legal Officer's share selling could have overshadowed these developments. This focus possibly swayed the stock's downward trajectory.
• An analysis hinting at Moderna's stock being potentially overvalued by InvestingPro may have further fueled the bearish sentiment. This suggestion might have prompted investors to reassess their positions, potentially triggering a sell-off.

11.05.2026 - MRNA Stock was up 5.2%

• Recent investment by Nicollet Investment Management Inc. reflects strong confidence in Moderna's future, potentially influencing the stock price.
• The success of Parabilis Medicines' IPO and positive news about a new drug candidate may have positively impacted investor sentiment towards the biotech industry, which could benefit Moderna.
• Letko Brosseau & Associates Inc. selling some of their Moderna shares might indicate a strategic move to capitalize on past stock price gains.
• Comparisons between NVIDIA and GLOBALFOUNDRIES showcasing positive attitudes towards tech and biotech stocks could indirectly support Moderna's upward movement.